Group 1 - The Hong Kong stock market opened slightly higher on October 2, with the Hang Seng Index at 26,918 points, up 62 points, a 0.23% increase [1] - Contemporary Amperex Technology Co., Limited (CATL) saw its stock price rise nearly 5%, surpassing 600 HKD, with a premium of 36.63% for its H-shares compared to its A-shares, which closed at 402 RMB [1] - New Ming China experienced a significant drop of over 80% in its stock price, reaching a low of 0.51 HKD, following a reported loss of 137 million HKD for the interim period [1] Group 2 - The technology sector showed mixed performance, with Kuaishou up over 4%, Alibaba and JD.com rising over 2%, while NetEase and Bilibili fell by over 2% and 1% respectively [1] - Gold stocks saw gains, with Zijin Mining International increasing by over 9%, and the innovative drug sector mostly opened higher, with 3SBio rising over 5% [1] - Galaxy Securities indicated that October is a critical window for policy layout, suggesting that both A-shares and Hong Kong stocks may benefit from long-term policy arrangements and a relatively loose liquidity environment [1]

Core Viewpoint - The Hong Kong stock market for innovative drug concepts has strengthened, with significant gains in various pharmaceutical companies following the postponement of drug tariffs by the Trump administration [1] Group 1: Market Performance - Companies such as Kelun-Biotech and Gilead Sciences saw their stock prices rise over 8% - Hengrui Medicine increased by over 6% - Companies like Tongyuan Kang Pharmaceutical and Xiansheng Pharmaceutical rose over 5% - Hansoh Pharmaceutical and Innovent Biologics gained over 4% - Companies such as Sihuan Pharmaceutical, Fuxing Pharmaceutical, Shiyao Group, and 3SBio increased by over 3% [1] Group 2: Regulatory Environment - President Trump had previously threatened to impose three-digit tariffs on drug imports starting Wednesday, but the White House indicated that these tariffs may not need to be implemented [1] Group 3: Industry Insights - Pacific Securities released a research report suggesting that attention should be paid to several factors: 1) Changes in Federal Reserve interest rate policies 2) Marginal changes in investment and financing 3) Gradual recovery of overseas demand 4) Sino-US relations and geopolitical factors 5) Class B medical insurance directory and commercial insurance [1]

Group 1 - The Hong Kong stock market opened slightly higher on October 2, with the Hang Seng Index at 26,918 points, up 62 points, a 0.23% increase [1] - Contemporary Amperex Technology Co., Limited (CATL) opened nearly 5% higher, with its stock price surpassing 600 HKD, reflecting a 36.63% premium of its H-shares over its A-shares, which closed at 402 RMB [1] - According to Pacific Securities, CATL's revenue for the first half of 2025 is projected to be 178.886 billion RMB, a 7.27% year-on-year increase, with net profit attributable to shareholders at 30.485 billion RMB, up 33.33% [3] Group 2 - CATL's global market share continues to lead, with steady growth in battery production and improved profitability, supported by an upgraded product matrix [3] - The company is accelerating its global layout and steadily advancing capacity construction, which is expected to enhance its competitive position in the power battery and energy storage sectors [3] - New Ming China experienced a significant drop in stock price, falling over 80% to a low of 0.51 HKD, following a mid-term loss of 137 million HKD, compared to a loss of 335 million HKD in the same period last year [3]

Group 1 - The Hong Kong stock market opened slightly higher on October 2, with the Hang Seng Index at 26,918 points, up 62 points, a 0.23% increase, and the Hang Seng Tech Index at 6,483 points, up 17 points, a 0.27% increase [2] - Contemporary Amperex Technology Co., Limited (CATL) opened nearly 5% higher, with its stock price surpassing 600 HKD. The premium of CATL's H-shares over its A-shares reached 36.63% as of the latest opening [3] - According to Pacific Securities, CATL's revenue for the first half of 2025 is projected to be 178.886 billion RMB, a 7.27% year-on-year increase, with net profit attributable to shareholders at 30.485 billion RMB, a 33.33% increase, and net profit excluding non-recurring items at 27.197 billion RMB, a 35.62% increase. The company maintains a leading global market share and is experiencing steady growth in battery production [5] Group 2 - New Ming China (02699.HK) saw its stock price drop over 80%, reaching a low of 0.51 HKD, resulting in a market capitalization of less than 60 million HKD. The company reported a mid-term loss of 137 million RMB, compared to a loss of 335 million RMB in the same period last year [5] - The technology sector showed mixed performance, with Kuaishou rising over 4%, Alibaba and JD.com up over 2%, while NetEase and Bilibili fell over 2% and 1%, respectively. Gold stocks saw gains, with Zijin Mining International up over 9%, and innovative drug concepts mostly opened higher, with 3SBio up over 5% [6] - Galaxy Securities indicated that October is a critical window for policy layout, with capital market expectations stable to rising. Both A-shares and Hong Kong stocks may benefit from long-term policy layouts, concentrated industrial catalytic events, and a relatively loose liquidity environment [7]

Group 1 - The Hong Kong stock market opened slightly higher on October 2, with the Hang Seng Index at 26,918 points, up 62 points, a 0.23% increase, and the Hang Seng Tech Index at 6,483 points, up 17 points, a 0.27% increase [1] - Contemporary Amperex Technology Co., Limited (CATL) opened nearly 5% higher, with its stock price surpassing 600 HKD. The premium of CATL's H-shares over its A-shares reached 36.63% as of today [3] - According to Pacific Securities, CATL achieved revenue of 178.886 billion RMB in the first half of 2025, a year-on-year increase of 7.27%, and a net profit attributable to shareholders of 30.485 billion RMB, up 33.33% year-on-year. The company continues to lead in global market share and battery production, with steady improvements in profitability and an accelerated global layout [5] Group 2 - New Ming China experienced a significant stock drop of over 80%, with its stock price hitting a low of 0.51 HKD, resulting in a market capitalization of less than 60 million HKD. The company reported a mid-term loss of 137 million RMB, compared to a loss of 335 million RMB in the same period last year [5] - In the market, tech stocks showed mixed performance, with Kuaishou rising over 4%, Alibaba and JD.com up over 2%, while NetEase and Bilibili fell over 2% and 1% respectively. Gold stocks saw gains, with Zijin Mining International up over 9% [7] - Galaxy Securities indicated that October is a critical window for policy layout, with expectations for the capital market to remain stable and potentially improve. Both A-shares and Hong Kong stocks may benefit from long-term policy layouts and a relatively loose liquidity environment [7]

Core Insights - The article highlights the strong performance of various mutual funds in China for the year-to-date, particularly in the equity and mixed fund categories, with average returns exceeding 35.4% for ordinary stock funds and 29.1% for mixed funds [2][3]. Fund Performance - The top-performing fund is the Yongying Technology Select Fund managed by Ren Jie, with a year-to-date return of approximately 194.49% [3][4]. - The second-best fund is the Huatai Hong Kong Advantage Select Fund managed by Zhang Wei, achieving a return of over 155% [3][14]. - The third position is held by the China Europe Digital Economy Fund managed by Feng Ludan, with a return of nearly 141% [3][4]. - In the bond fund category, the Southern Changyuan Convertible Bond Fund managed by Liu Wenliang leads with a return of 44.21%, outperforming many equity funds [15]. Sector-Specific Insights - The article notes that funds focused on specific sectors, such as technology and healthcare, have shown exceptional performance, with many funds achieving returns exceeding 100% [5][6]. - The Huazhong Medical Biology Fund, managed by Sang Xiangyu, achieved a return of 103.31%, reclaiming the top position among ordinary stock funds [5][7]. - The article emphasizes that without a return of at least 110%, funds could not make it into the top twenty performers this year [2]. Index Fund Performance - In the index fund category, the top three funds are all focused on innovative pharmaceuticals, with returns exceeding 106% [10][12]. - The Wanji Zhongzheng Hong Kong Stock Connect Innovative Drug ETF, managed by He Fangzhou, leads with a return of 114.01% [12][10]. QDII Fund Insights - QDII funds have predominantly invested in Hong Kong stocks, with the top-performing fund being the Huatai Hong Kong Advantage Select Fund, achieving a return of over 155% [13][14]. - Other notable QDII funds include the Guangfa Zhongzheng Hong Kong Innovative Drug ETF and the Yifangda Global Pharmaceutical Industry Fund, both exceeding 100% returns [13][14]. Bond Fund Insights - The Southern Changyuan Convertible Bond Fund, with a return of 44.21%, showcases the strong performance of bond funds this year, attributed to their equity components [15].

(於開曼群島註冊成立的有限公司 ) 股份代號：01530 目錄 2 公司概覽 3 公司資料 5 財務摘要 6 管理層討論及分析 26 企業管治及其他資料 37 獨立審閱報告 39 中期簡明綜合損益表 40 中期簡明綜合全面收益表 41 中期簡明綜合財務狀況表 43 中期簡明綜合權益變動表 45 中期簡明綜合現金流量表 47 中期簡明綜合財務資料附註 公司概覽 三生制药（「本公司」或「三生制药」，連同其附屬公司統稱「本集團」）為中華人民共和國（「中國」）領先的生物技術公司。本集團作為 中國生物技術行業的先鋒，在研發、生產及營銷生物醫藥產品方面擁有豐富的經驗。本集團的核心商業化產品包括多種生物藥 物，即特比澳、重組人促紅素（「rhEPO」）產品益比奧及賽博爾、益賽普和賽普汀，以及小分子藥物蔓迪。特比澳為當今全球唯一 商業化的重組人血小板生成素（「rhTPO」）產品。根據IQVIA1，於二零二五年上半年，按銷售額計，特比澳在中國內地2血小板減少 症治療市場的份額為63.0%。憑藉兩種rhEPO產品，二十多年來，本集團一直為中國內地rhEPO市場龍頭，於二零二五年上半年共 佔41.5%的總市場份額。益賽普為中國內地市 ...

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - China's rich pool of engineers and scientists, along with efficient and cost-effective clinical trials and drug manufacturing capabilities, are seen as core competitive advantages for pharmaceutical innovation [2] - The impact of the US imposing tariffs on innovative drugs is expected to be limited for the CXO sector, as many multinational pharmaceutical companies already have plans to build factories in the US [2] - Future growth in innovative drugs is anticipated to be driven by overseas partners pushing clinical development for licensed pipelines [2]

Group 1 - The core viewpoint is that the collaboration between China and the US in innovation is expected to continue, with a recovery in domestic innovation and R&D demand in China [1][2] - The MSCI China Healthcare Index has increased by 74.0% since the beginning of 2025, outperforming the MSCI China Index by 37.3% [1] - The price for experimental monkeys, essential for innovative drug R&D, has risen from approximately 85,000 yuan in mid-2024 to about 90,000 yuan [1] Group 2 - The US is expected to impose tariffs on innovative drugs, but the impact on the CXO sector is anticipated to be limited [2] - Trump's announcement on September 25 states that unless pharmaceutical companies are building factories in the US, patented drugs will face a 100% tariff starting October 1 [2] - The continuous upward momentum for innovative drugs is expected to primarily come from overseas partners pushing clinical developments for authorized pipelines [2]

Group 1 - The long-term potential of China's healthcare market remains optimistic, but the pharmaceutical sector has surged 64% this year due to licensing optimism, leading to a shift in market focus towards organic revenue/profit growth due to rising risks from potential U.S. executive orders and high valuations [1][2] - UBS downgraded the ratings of CSPC Pharmaceutical Group (01093) and Kelun Pharmaceutical (002422.SZ) to "Neutral" based on weak fundamentals, while changing its industry preference from 3SBio (01530) to Hansoh Pharmaceutical (03692) due to its stable traditional business and innovative pipeline [1] - The report indicates that the forward P/E ratio of Chinese pharmaceutical stocks is above the five-year average, with increasing risks from U.S. executive orders shifting market focus back to organic growth [1] Group 2 - CSPC's core traditional product NBP, which accounts for 32% of its 2024 finished drug revenue, continues to lose market share, and its high dependence on unconfirmed business development revenue increases uncertainty [2] - Kelun Pharmaceutical faces weak demand and intense competition, which may result in the lowest revenue growth among peers by 2025 [2] - The expected compound annual growth rate (CAGR) for CSPC and Kelun from 2024 to 2034 is only half of the average 13% CAGR of 3SBio, Hansoh, and Innovent Biologics [1]